CEO COMMENTS
Kristina Torfgård comments Q1 report 2025
“The first quarter of 2025 has been one of our most dynamic to date, marked by significant regulatory progress, promising clinical results, and the deepening of strategically important partnerships, all collectively strengthening our position. Following an in-depth analysis of the topline data for pirepemat presented during the quarter, we can confidently affirm that all of our development programs continue to make evident progress and bring us closer to our goal – to provide new, effective treatments for people living with Parkinson’s disease.
Key Milestones During the Quarter:
- Promising results from the Phase I study with IRL757 enable the next step in clinical development – a study in patients with Parkinson’s and apathy. Our strategic collaboration with MSRD/Otsuka and the Michael J. Fox Foundation plays an important role in advancing the development of IRL757.
- The regulatory progress for mesdopetam lays a strong foundation for the upcoming Phase III program and deepened discussions with potential partners.
- Study data on pirepemat show a statistically significant and clinically meaningful reduction in fall rate, linked to the plasma concentrations of the drug.
Together, these advances demonstrate that we are well on our way to realizing our vision and creating value for patients, partners and shareholders.”
LATEST REPORTS
Report from the Annual General Meeting 2025 of IRLAB Therapeutics AB
Today, on Wednesday June 11, 2025, IRLAB Therapeutics AB held its Annual General Meeting.
Read More >
Presentation at Redeye’s Theme Event Neurology
Presentation by Kristina Torfgård, CEO, at “Theme Event Neurology”, an event hosted by Redeye, held on October 23, 2024.
Read More >FINANCIAL CALENDAR
NEXT
August 27 2025
Interim Report January – June 2025